Invesco
RNAC icon

Invesco’s Cartesian Therapeutics RNAC Stock Holding History

Invesco’s Portfolio RNAC Stock Details RNAC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-8,157
Closed -$159K – 3957
2024
Q1 		$159K Buy
8,157
+6,339
+349% +$134K ﹤0.01% 3688
2023
Q4 		$37.6K Sell
1,818
-783
-30% -$23.4K ﹤0.01% 3772
2023
Q3 		$82.7K Sell
2,601
-40
-2% -$1.34K ﹤0.01% 3747
2023
Q2 		$88.7K Buy
2,641
+1,971
+294% +$70.5K ﹤0.01% 3749
2023
Q1 		$27.9K Sell
670
-23
-3% -$1.08K ﹤0.01% 3794
2022
Q4 		$23.5K Buy
+693
New +$29.5K ﹤0.01% 3964
2022
Q2 		– Sell
-999
Closed -$37K – 4126
2022
Q1 		$37K Buy
999
+59
+6% +$3.69K ﹤0.01% 3952
2021
Q4 		$92K Sell
940
-172
-15% -$18.5K ﹤0.01% 3915
2021
Q3 		$139K Buy
1,112
+141
+15% +$17K ﹤0.01% 3881
2021
Q2 		$122K Buy
971
+84
+9% +$10K ﹤0.01% 3869
2021
Q1 		$120K Buy
887
+63
+8% +$7.82K ﹤0.01% 3741
2020
Q4 		$75K Buy
+824
New +$71.5K ﹤0.01% 3687

Other funds holding RNAC

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
EAM
Erste Asset Management Vienna, Austria $10.8B AUM 38.54% 1-Year Est. Return

Invesco's RNAC Position: Q2 2024 in Review

Invesco sold out of Cartesian Therapeutics (RNAC) in Q2 2024, closing a stake of 8,157 shares — an estimated $159K sold.

Invesco first reported a position in RNAC in Q4 2020 and held it in 12 quarters. The position peaked at $159K in Q1 2024. 61 funds tracked by Wall St. Rank hold RNAC as of Q2 2024.

  • Invesco reported no remaining Cartesian Therapeutics position as of Q2 2024 after selling out during the quarter.
  • Invesco sold 8,157 Cartesian Therapeutics shares in Q2 2024, an estimated $159K.
  • Invesco first reported a position in Cartesian Therapeutics in Q4 2020 and held it in 12 quarters.
  • Invesco's Cartesian Therapeutics position peaked at $159K in Q1 2024.
  • 61 funds tracked by Wall St. Rank held Cartesian Therapeutics as of Q2 2024.

Based on Invesco's 13F filing for Q2 2024, filed 13 Aug 2024.